Iovance Biotherapeutics (IOVA) Competitors $2.38 +0.17 (+7.69%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$2.39 +0.01 (+0.42%) As of 04:53 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IOVA vs. AMRX, XENE, MIRM, ARWR, LYEL, AAPG, NAMS, BLTE, VERA, and HRMYShould you be buying Iovance Biotherapeutics stock or one of its competitors? The main competitors of Iovance Biotherapeutics include Amneal Pharmaceuticals (AMRX), Xenon Pharmaceuticals (XENE), Mirum Pharmaceuticals (MIRM), Arrowhead Pharmaceuticals (ARWR), Lyell Immunopharma (LYEL), Ascentage Pharma Group International (AAPG), NewAmsterdam Pharma (NAMS), Belite Bio (BLTE), Vera Therapeutics (VERA), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry. Iovance Biotherapeutics vs. Amneal Pharmaceuticals Xenon Pharmaceuticals Mirum Pharmaceuticals Arrowhead Pharmaceuticals Lyell Immunopharma Ascentage Pharma Group International NewAmsterdam Pharma Belite Bio Vera Therapeutics Harmony Biosciences Iovance Biotherapeutics (NASDAQ:IOVA) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, community ranking, media sentiment, dividends, risk, profitability and institutional ownership. Is IOVA or AMRX more profitable? Amneal Pharmaceuticals has a net margin of -6.88% compared to Iovance Biotherapeutics' net margin of -451.25%. Iovance Biotherapeutics' return on equity of -58.43% beat Amneal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Iovance Biotherapeutics-451.25% -58.43% -45.48% Amneal Pharmaceuticals -6.88%-346.26%4.85% Which has better earnings and valuation, IOVA or AMRX? Amneal Pharmaceuticals has higher revenue and earnings than Iovance Biotherapeutics. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIovance Biotherapeutics$212.68M3.74-$444.04M-$1.24-1.92Amneal Pharmaceuticals$2.83B0.86-$83.99M-$0.04-195.25 Which has more volatility & risk, IOVA or AMRX? Iovance Biotherapeutics has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Does the MarketBeat Community prefer IOVA or AMRX? Iovance Biotherapeutics received 556 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 95.45% of users gave Amneal Pharmaceuticals an outperform vote while only 74.16% of users gave Iovance Biotherapeutics an outperform vote. CompanyUnderperformOutperformIovance BiotherapeuticsOutperform Votes57774.16% Underperform Votes20125.84% Amneal PharmaceuticalsOutperform Votes2195.45% Underperform Votes14.55% Do analysts prefer IOVA or AMRX? Iovance Biotherapeutics currently has a consensus price target of $13.30, indicating a potential upside of 458.82%. Amneal Pharmaceuticals has a consensus price target of $11.60, indicating a potential upside of 48.53%. Given Iovance Biotherapeutics' higher possible upside, research analysts plainly believe Iovance Biotherapeutics is more favorable than Amneal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iovance Biotherapeutics 0 Sell rating(s) 6 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.50Amneal Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor IOVA or AMRX? In the previous week, Iovance Biotherapeutics had 29 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 40 mentions for Iovance Biotherapeutics and 11 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.54 beat Iovance Biotherapeutics' score of 0.06 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 2 Very Positive mention(s) 1 Positive mention(s) 36 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amneal Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in IOVA or AMRX? 77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 10.3% of Iovance Biotherapeutics shares are held by insiders. Comparatively, 26.6% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryAmneal Pharmaceuticals beats Iovance Biotherapeutics on 10 of the 18 factors compared between the two stocks. Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IOVA vs. The Competition Export to ExcelMetricIovance BiotherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$794.76M$3.10B$5.57B$8.67BDividend YieldN/A1.59%5.27%4.19%P/E Ratio-1.6033.8227.2220.17Price / Sales3.74476.37421.92161.94Price / CashN/A168.6838.2534.64Price / Book1.043.497.124.72Net Income-$444.04M-$72.35M$3.23B$247.80M7 Day Performance30.05%9.39%3.79%2.76%1 Month Performance36.00%24.23%13.35%9.71%1 Year Performance-72.39%-16.25%32.04%14.51% Iovance Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IOVAIovance Biotherapeutics4.5572 of 5 stars$2.38+7.7%$13.30+458.8%-70.5%$794.76M$212.68M-1.60500Trending NewsHigh Trading VolumeAMRXAmneal Pharmaceuticals3.7159 of 5 stars$7.42+1.3%$11.50+55.1%+14.0%$2.32B$2.83B-10.907,600XENEXenon Pharmaceuticals3.4398 of 5 stars$30.05+4.2%$54.82+82.4%-15.9%$2.31B$7.50M-10.66210Positive NewsAnalyst RevisionMIRMMirum Pharmaceuticals2.942 of 5 stars$46.07+3.6%$60.73+31.8%+91.7%$2.28B$379.25M-22.78140ARWRArrowhead Pharmaceuticals3.7269 of 5 stars$16.39+2.0%$42.13+157.0%-30.8%$2.26B$545.21M-3.17400LYELLyell Immunopharma2.2264 of 5 stars$7.68-12.1%$1.00-87.0%-77.1%$2.26B$65,000.00-9.67270High Trading VolumeAAPGAscentage Pharma Group InternationalN/A$25.00+2.5%N/AN/A$2.18B$980.65M0.00600NAMSNewAmsterdam Pharma2.6748 of 5 stars$18.96+4.7%$43.00+126.8%+11.0%$2.12B$47.14M-10.054Trending NewsAnalyst ForecastAnalyst RevisionGap UpBLTEBelite Bio2.2596 of 5 stars$65.83+1.5%$96.67+46.8%+24.8%$2.08BN/A-58.9910VERAVera Therapeutics2.8269 of 5 stars$32.61+72.1%$65.00+99.3%-42.0%$2.08BN/A-12.5040High Trading VolumeHRMYHarmony Biosciences4.9545 of 5 stars$35.58+3.1%$53.00+49.0%+19.8%$2.04B$744.85M16.86200Positive News Related Companies and Tools Related Companies Amneal Pharmaceuticals Competitors Xenon Pharmaceuticals Competitors Mirum Pharmaceuticals Competitors Arrowhead Pharmaceuticals Competitors Lyell Immunopharma Competitors Ascentage Pharma Group International Competitors NewAmsterdam Pharma Competitors Belite Bio Competitors Vera Therapeutics Competitors Harmony Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IOVA) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
